Novartis presents positive results from the pivotal phase III ASC4FIRST trial as a late-breaking abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting. Scemblix (asciminib) demonstrated superior major molecular response (MMR) rates at week 48 compared to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) imatinib, nilotinib, dasatinib and bosutinib, and compared to imatinib alone in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase (Ph+ CML-CP). Scemblix also showed a numerical improvement in MMR at week 48 vs. second generation (2G) TKIs (nilotinib, dasatinib and bosutinib). Additionally, Scemblix demonstrated a favourable safety and tolerability profile, with fewer adverse events (AEs) and treatment discontinuations vs. both imatinib and 2G TKIs.
Xspray to present data at ASCO highlighting frequent comedication of PPIs with TKIs in CML-patients and greater than expected negative effects on the bioavailability of crystalline dasatinib
Teva`s Generic Dasatinib Receives Approval in the U.S.
Teva Pharma Generic Dasatinib Receives Tentative Approval in US
Accord Healthcare Dasatinib Receives Approval in Europe
Alembic Pharma's Generic Dasatinib Receives Approval in the U.S.
Bristol-Myers Squibb Co. filed a lawsuit alleging XSpray Pharma AB’s proposed branded generic version of Sprycel tablets infringes two patents for the blockbuster leukemia drug, which generated more revenue last year than all but five of Bristol-Myers’ products.
Health Canada Issues Recall of Reddy-Dasatinib: out of specification
Researchers from the Institute of Cancer Research (ICR), London, UK, have identified a new combination of two approved cancer drugs that can be used to treat children suffering from incurable brain cancer.
Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) announces today that it has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric pH level. HyNap-Dasa is being developed both as a generic and improved version of the marketed drug Sprycel® (dasatinib).